Citations 1
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Alwan, Laura, Bachiashvili, Kimo, Cool, Rita, Curtin, Peter , Dinner, Shira, Gojo, Ivana , Hicks, Ashley, Kidwai, Wajih Zaheer, Kloth, Dwight D. , Kraut, Eric H., Miller, Ryan, Patel, Shiven B. , Perez, Lia, Poust, Adam, Rampal, Raajit K. , Shayani, Sepideh, Vasu, Sumithira , Wadleigh, Martha , Westbrook, Kelly, Westervelt, Peter, Burns, Jennifer L. , Keller, Jennifer , Pluchino, Lenora A. , Westbrook, Kelly , Becker, Pamela S. , Griffiths, Elizabeth A. , Brown, Anna Mary , Kallam, Avyakta , Landsburg, Daniel J. , Lyman, Gary H , Mukherjee, Sudipto , Rosovsky, Rachel , Roy, Vivek , Rugo, Hope S.
Journal of the National Comprehensive Cancer Network | January 7, 2020 | Volume: 18 | Issue: 1 | Pages: 12-22
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.